Agios Pharmaceuticals, Inc (AGIO)

Etorro trading 970x250
Agios Pharmaceuticals, Inc (AGIO) Logo

About Agios Pharmaceuticals, Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139-4169

Agios Pharmaceuticals, Inc News and around…

Latest news about Agios Pharmaceuticals, Inc (AGIO) common stock and company :

Scientist behind Vertex CF drugs launches new startup with Atlas Venture
14 Oct, 2021 Yahoo! Finance

Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture called Rectify Pharmaceuticals.

Analysts Expect 42% Gains Ahead For The Holdings of WDNA
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $35.26 per unit.

Top Biotech Stocks for Q4 2021
20 Sep, 2021 Yahoo! Finance

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Agios To Present at September Investor Conferences
30 Aug, 2021 FinancialContent
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
25 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day. The post 7 Best Biotech Stocks to Buy in 2021 with Huge Upside appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
18 Aug, 2021 Yahoo! Finance

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Agios' Rare Anemia Drug Application Under FDA Priority Review
18 Aug, 2021 FinancialContent

TheFDA has acceptedAgios Pharmaceuticals Inc's(NASDAQ: AGIO) marketing application seeking approval for ...

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
17 Aug, 2021 FinancialContent

-- PDUFA Date Set for February 17, 2022 --

Would Shareholders Who Purchased Agios Pharmaceuticals' (NASDAQ:AGIO) Stock Three Years Be Happy With The Share price Today?
31 Jul, 2021 Yahoo! Finance

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
30 Jul, 2021 Yahoo! Finance

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021
30 Jul, 2021 FinancialContent

Upgrades According to Craig-Hallum, the prior rating for Gentherm Inc (NASDAQ:THRM) was changed from Hold to Buy. For ...

We Did The Math FBT Can Go To $206
30 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $205.81 per unit.

Agios Pharmaceuticals, inc (AGIO) Q2 2021 Earnings Call Transcript
29 Jul, 2021 FinancialContent

AGIO earnings call for the period ending June 30, 2021.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates
29 Jul, 2021 Yahoo! Finance

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Agios Reports Business Highlights and Second Quarter 2021 Financial Results
29 Jul, 2021 FinancialContent
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
25 Jul, 2021 FinancialContent

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism ...

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
22 Jul, 2021 Yahoo! Finance

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is What Hedge Funds Think About Agios Pharmaceuticals Inc (AGIO)
19 Jul, 2021 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
15 Jul, 2021 FinancialContent
Agios Pharmaceuticals Sees RS Rating Improve To 72
12 Jul, 2021 FinancialContent

Agios Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021
01 Jul, 2021 FinancialContent

Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE:THO) from Neutral to Buy. For the third quarter, Thor ...

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
29 Jun, 2021 Yahoo! Finance

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
28 Jun, 2021 FinancialContent
Add Up The Pieces: FXH Could Be Worth $129
24 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Health Care AlphaDEX Fund ETF (FXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $129.27 per unit.

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
22 Jun, 2021 Yahoo! Finance

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
22 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
22 Jun, 2021 FinancialContent
Notable Monday Option Activity: AGIO, MRNA, AZO
21 Jun, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Agios Pharmaceuticals Inc (AGIO), where a total of 3,348 contracts have traded so far, representing approximately 334,800 underlying shares. That amounts to about 67.2% of AGIO's average daily trading volume over the past month of 497,845 shares..

Agios Pharmaceuticals, Inc (AGIO) is a NASDAQ Common Stock listed in , ,

970x250